Evidence map›Paper›PMID 35697828›Full record

ArticleScientific reports2022

Predictive factors for the presence and long-term persistence of SARS-CoV-2 antibodies in healthcare and university workers.

Céline Grégoire, Pascale Huynen, Stéphanie Gofflot, Laurence Seidel, Nathalie Maes, Laura Vranken, Sandra Delcour, Michel Moutschen, Marie-Pierre Hayette, Philippe Kolh and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Céline Grégoire *Division of Hematology, CHU Sart-Tilman, Avenue de l'hôpital 1, 4000, Liège, Belgium. celine.gregoire@chuliege.be.
Pascale Huynen *Division of Medical Microbiology, Unilab, CHU of Liège, Liège, Belgium.
Stéphanie GofflotBiothèque Hospitalo-Universitaire de Liège (BHUL), CHU of Liège, Liège, Belgium.
Laurence SeidelDepartment of Biostatistics and Medico-Economic Information, CHU of Liège, Liège, Belgium.
Nathalie MaesDepartment of Biostatistics and Medico-Economic Information, CHU of Liège, Liège, Belgium.
Laura VrankenUnilab, CHU of Liège, Liège, Belgium.
Sandra DelcourUnilab, CHU of Liège, Liège, Belgium.
Michel MoutschenDivision of Infectious Diseases and General Internal Medicine, CHU of Liège, Liège, Belgium.
Marie-Pierre HayetteDivision of Medical Microbiology, Unilab, CHU of Liège, Liège, Belgium.
Philippe KolhDepartment of Information System Management, CHU of Liège, Liège, Belgium.
Pierrette MelinDivision of Medical Microbiology, Unilab, CHU of Liège, Liège, Belgium.
Yves BeguinDivision of Hematology, CHU Sart-Tilman, Avenue de l'hôpital 1, 4000, Liège, Belgium.
University of Liège · BECentre Hospitalier Universitaire de Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While patient groups at risk for severe COVID-19 infections are now well identified, the risk factors associated with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) transmission and immunization are still poorly understood. In a cohort of staff members of a Belgian tertiary academic hospital tested for SARS-CoV-2 antibodies during the early phase of the pandemic and followed-up after 6 weeks, 3 months and 10 months, we collected personal, occupational and medical data, as well as symptoms based on which we constructed a COVID-19 score. Seroprevalence was higher among participants in contact with patients or with COVID-19 confirmed subjects or, to a lesser extent, among those handling respiratory specimens, as well as among participants reporting an immunodeficiency or a previous or active hematological malignancy, and correlated with several symptoms. In multivariate analysis, variables associated with seropositivity were: contact with COVID-19 patients, immunodeficiency, previous or active hematological malignancy, anosmia, cough, nasal symptoms, myalgia, and fever. At 10 months, participants in contact with patients and those with higher initial COVID-19 scores were more likely to have sustained antibodies, whereas those with solid tumors or taking chronic medications were at higher risk to become seronegative.

Indexed as

COVID-19Hematologic NeoplasmsAntibodies, ViralDelivery of Health CareHealth PersonnelHumansSARS-CoV-2Seroepidemiologic StudiesUniversitiesAntibodies, Viral

Identifiers

PMID35697828
PMCPMC9191528
OpenAlexW4282592142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.